English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 860857      Online Users : 931
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version

    Category

    Loading community tree, please wait....

    Year

    Loading year class tree, please wait....

    Items for Author "Qin, S" 

    Return to Browse by Author

    Showing 11 items.

    Collection Date Title Relation Bitstream
    [陳立宗] 期刊論文 2018-06 Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma -
    [陳立宗] 會議論文/會議摘要 2019-10 A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 -
    [陳立宗] 期刊論文 2020-03 Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO -
    [陳立宗] 會議論文/會議摘要 2022-02-01 A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 -
    [陳為堅] 期刊論文 2022-04-08 Mapping genomic loci implicates genes and synaptic biology in schizophrenia -
    [林彥鋒] 期刊論文 2022-05-05 Improving polygenic prediction in ancestrally diverse populations -
    [林彥鋒] 期刊論文 2022-07-04 Improving polygenic prediction in ancestrally diverse populations [Erratum:Nature Genetics. 2022 May 5;54(5):573-580.] -
    [陳立宗] 會議論文/會議摘要 2022-09 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) -
    [陳立宗] 會議論文/會議摘要 2022-11 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) -
    [陳立宗] 期刊論文 2023-07 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462 -
    [陳立宗] 期刊論文 2024-08 Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study -

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback